Cannabinoid Medication for Adults With OCD
关键词
抽象
日期
| 最后验证: | 01/31/2020 |
| 首次提交: | 09/11/2016 |
| 提交的预估入学人数: | 09/19/2016 |
| 首次发布: | 09/21/2016 |
| 上次提交的更新: | 02/26/2020 |
| 最近更新发布: | 02/27/2020 |
| 首次提交结果的日期: | 01/09/2020 |
| 首次提交质量检查结果的日期: | 02/26/2020 |
| 首次发布结果的日期: | 02/27/2020 |
| 实际学习开始日期: | 08/31/2016 |
| 预计主要完成日期: | 12/31/2018 |
| 预计完成日期: | 12/31/2018 |
状况或疾病
干预/治疗
Drug: Nabilone
Behavioral: Nabilone and EX/RP
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Experimental: Nabilone Will receive nabilone at 1 mg daily (BID) over 4 weeks. | |
| Experimental: Nabilone and EX/RP Will receive nabilone at 1 mg daily (BID) plus therapist-guided Exposure and Response Prevention Therapy during 4 weeks. | Behavioral: Nabilone and EX/RP Exposure and Response Prevention Therapy (EX/RP) is a type of Cognitive-Behavioral Therapy for OCD that involves intentionally confronting situations that trigger obsessional distress while refraining from doing compulsions. |
资格标准
| 有资格学习的年龄 | 18 Years 至 18 Years |
| 有资格学习的性别 | All |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: - Age 18-60 - Physically healthy, not pregnant - Primary Obsessive-Compulsive Disorder (OCD) - Patient off all psychotropic (except selective serotonin reuptake inhibitors [SSRIs]) and other types of drugs likely to interact with nabilone - Ability to provide informed consent - Ability to tolerate a treatment free-period Exclusion Criteria: - History of any significant medical condition that may increase the risk of participation - Females who are pregnant or nursing - Current or lifetime history of psychiatric disorders other than OCD that may increase the risk of participation (e.g. lifetime psychosis or bipolar disorder) - Current substance use disorder or positive urine toxicology at screening, or any adverse reaction to a cannabinoid - Patients already receiving EX/RP |
结果
主要结果指标
1. Change in Yale-Brown Obsessive Compulsive Scale [Baseline (Week 0) and Week 4]
次要成果指标
1. Feasibility of Recruitment [Through study completion, an average of 1 year.]
